{"filing":{"accession_number":"0001193125-26-430681","cik":"0001768446","ticker":"CLYM","company_name":"Climb Bio, Inc.","form":"8-K","filing_date":"2026-10-23","report_date":"2026-10-23","primary_document":"clym-20261023.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1768446/000119312526430681/clym-20261023.htm"},"events":[{"id":37715,"run_id":34756,"accession_number":"0001193125-26-430681","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Climb Bio announced positive Phase 1 clinical trial data for CLYM116/MIL116 presented at ASN Kidney Week 2026, demonstrating favorable pharmacokinetic and pharmacodynamic results including ~70% Gd-IgA1 reduction, \u003e90% APRIL suppression, and a ~33-day half-life supporting Q12W dosing. The data support advancement to Phase 2 (NAVIGATE-2, currently enrolling) and planned Phase 3 initiation in 2027, representing a material clinical development milestone for the company's lead program in IgA nephropathy.","company_name":"Climb Bio, Inc.","ticker":"CLYM","filing_date":"2026-10-23","form":"8-K","submitted_at":null,"items":[{"id":42512,"accession_number":"0001193125-26-430681","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Climb Bio announced Phase 1 clinical trial data for CLYM116/MIL116 presented at ASN Kidney Week 2026, demonstrating favorable pharmacokinetic and pharmacodynamic results including ~70% Gd-IgA1 reduction and a ~33-day half-life supporting Q12W dosing. This is a material clinical development milestone for an early-stage biotech company's lead program, affecting investor assessment of pipeline progress and regulatory pathway, though it does not fit the specific categories of earnings release, M\u0026A, impairment, or other defined event types.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-23T21:27:41.811991+00:00","company_name":"","ticker":null,"filing_date":""},{"id":42513,"accession_number":"0001193125-26-430681","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This disclosure announces positive Phase 1 clinical trial data for CLYM116, a lead product candidate in development for IgA nephropathy. The filing reports favorable pharmacokinetic and pharmacodynamic results (33-day half-life, \u003e90% APRIL suppression through 12 weeks, ~70% Gd-IgA1 reduction) and a favorable safety profile, supporting advancement to Phase 2 (NAVIGATE-2, currently enrolling) and planned Phase 3 initiation in 2027. While this is a clinical development milestone rather than a specific named event type (not earnings, M\u0026A, impairment, etc.), it is a material operational/strategic disclosure affecting investor assessment of the company's pipeline progress and competitive positioning in immunotherapy.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-23T21:27:41.811991+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":42512,"accession_number":"0001193125-26-430681","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Climb Bio announced Phase 1 clinical trial data for CLYM116/MIL116 presented at ASN Kidney Week 2026, demonstrating favorable pharmacokinetic and pharmacodynamic results including ~70% Gd-IgA1 reduction and a ~33-day half-life supporting Q12W dosing. This is a material clinical development milestone for an early-stage biotech company's lead program, affecting investor assessment of pipeline progress and regulatory pathway, though it does not fit the specific categories of earnings release, M\u0026A, impairment, or other defined event types.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-23T21:27:41.811991+00:00","company_name":"Climb Bio, Inc.","ticker":"CLYM","filing_date":"2026-10-23"},{"id":42513,"accession_number":"0001193125-26-430681","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This disclosure announces positive Phase 1 clinical trial data for CLYM116, a lead product candidate in development for IgA nephropathy. The filing reports favorable pharmacokinetic and pharmacodynamic results (33-day half-life, \u003e90% APRIL suppression through 12 weeks, ~70% Gd-IgA1 reduction) and a favorable safety profile, supporting advancement to Phase 2 (NAVIGATE-2, currently enrolling) and planned Phase 3 initiation in 2027. While this is a clinical development milestone rather than a specific named event type (not earnings, M\u0026A, impairment, etc.), it is a material operational/strategic disclosure affecting investor assessment of the company's pipeline progress and competitive positioning in immunotherapy.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-23T21:27:41.811991+00:00","company_name":"Climb Bio, Inc.","ticker":"CLYM","filing_date":"2026-10-23"}]}